预约演示
更新于：2026-10-23
Orlistat
奥利司他
更新于：2026-10-23
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C29H53NO5 |
InChIKeyAHLBNYSZXLDEJQ-FWEHEUNISA-N |
CAS号96829-58-2 |
关联
107
项与 奥利司他 相关的临床试验NCT07714070
A Single-Center, Randomized, Open-Label, Controlled Trial of Orlistat Combined With Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Endometrial Hyperplasia With Low Progesterone Receptor Expression
PACTR202606518409008
The Effect of Metformin versus Orlistat on Cardiovascular and Metabolic profile in Obese Children: A Randomized Control Trial
NCT07301437
A Real-world Study of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.
100 项与 奥利司他 相关的临床结果
登录后查看更多信息
100 项与 奥利司他 相关的转化医学
登录后查看更多信息
100 项与 奥利司他 相关的专利（医药）
登录后查看更多信息
2,640
项与 奥利司他 相关的文献（医药）2026-12-31Artificial Cells Nanomedicine and Biotechnology
Green synthesis of ZnO nanoparticles using pomegranate husk extract: comparative evaluation of antioxidant, enzyme inhibition, and cytotoxic properties
Article
作者: Li, Fang ; Djearamane, Sinouvassane ; Lim, Sharon Chia-Yen ; Wong, Ling-Shing ; Lim, Boon-Hoe ; Cheah, Shi-Yan ; Tey, Lai-Hock ; Koh, Ming-Xiu ; Aminuzzaman, Mohammod ; Subramaniam, Hemaroopini ; Phang, You-Kang
The prevalence of obesity has risen sharply in recent years, prompting the need for safer and more biocompatible therapeutic alternatives to conventional anti-obesity drugs. In this study, zinc oxide nanoparticles (ZnO NPs) were synthesized using pomegranate husk extract via two green approaches: conventional heating and microwave-assisted synthesis. Structural and morphological characterizations confirmed successful nanoparticle formation. Microwave-assisted ZnO nanoparticles (MA-ZnO NPs) exhibited smaller particle dimensions and narrower polydispersity compared with conventionally synthesized ZnO NPs. Both types of ZnO NPs demonstrated notable antioxidant activity (>62% scavenging in DPPH and ABTS assays) and strong inhibitory effects against pancreatic lipase and α-amylase (>70%), comparable to standard drugs such as orlistat and acarbose. Cytotoxicity assays using Vero cells confirmed high biocompatibility, with >60% cell viability. This work presents a comparative evaluation of two green synthesis methods and highlights the potential of biogenic ZnO NPs as multifunctional agents for oxidative stress reduction and enzyme inhibition in obesity management.
2026-12-01MOLECULAR BIOLOGY REPORTS
Pharmacological inhibition of IRAK1/4 ameliorates high-fat diet-induced vascular dysfunction and cognitive impairment
Article
作者: Barthwal, Manoj Kumar ; Yadav, Prem N ; Agarwal, Heena ; Kumar, Dinesh ; Kumar, Sakesh ; Kaur, Gagandeep
PURPOSE:
Interleukin 1 receptor-associated kinase 1, 4 (IRAK 1/4) inhibitor exerts anti-inflammatory and immuno-modulatory effects; however, its role in high-fat diet-induced vascular dysfunction and cognitive impairment is not known, and therefore investigated in the present study.
METHOD & RESULTS:
Animals were fed either a high-fat diet (60% Kcal fat) or a chow diet (10% Kcal fat) for 12 weeks to induce hyperlipidemia and weight gain. High-fat diet-fed animals were then treated with vehicle, IRAK1/4 inhibitor (2.2 mg/kg, i.p.) and a reference drug, Orlistat (20 mg/kg, oral gavage), for 4 additional weeks. Protein levels were assessed by ELISA or Western blotting, and mRNA by RT-PCR. IRAK1/4 inhibitor and reference drug, Orlistat treatment, prevented HFD-induced increase in body weight gain, fasting blood glucose and plasma lipids, improved discrimination between the familiar and the novel arm in the Y-Maze test, alleviated percent avoidance in two-way active avoidance, and freezing percent in contextual fear conditioning test. The treatments attenuated the levels of systemic inflammatory cytokines IL-1β, CRP, as well as TNF-α, IL-6 and protein expression of Iba-1, GFAP, HIF-1α, and restored the BDNF levels in the pre-frontal cortex of HFD-fed treated mice. IRAK 1/4 inhibitor exerted these effects by blocking proteasomal degradation of IκB-α protein in the pre-frontal cortex of HFD-treated mice. In addition, the treatments prevented HFD-induced increase in vascular ICAM-1, VCAM-1, MCP-1, COX-1 and COX-2 mRNA expression, and restored vascular eNOS mRNA levels as well as the Acetylcholine (300 ρM-300 μM) induced relaxations of PE (1 µM) pre-contracted aortic rings.
CONCLUSION:
IRAK1/4 inhibitor attenuates HFD-induced inflammation, vascular dysfunction and cognitive impairment in obese mice.
2026-11-01CELLULAR SIGNALLING
Targeting lipoprotein lipase-positive macrophage-driven GDF-15 expression alleviates cancer Cachexia in obese head and neck squamous cell carcinoma
Article
作者: Zhao, Ran ; Guo, Yu-Jia ; Zhao, Meng-Ran ; Cui, Jing-Jing ; Yang, Yang ; Wu, Jun-Yao ; Song, Xiaomeng ; Zhao, Jia-Hao ; Li, Yue-Han
Head and neck squamous cell carcinoma (HNSCC) is often associated with dysphagia and malnutrition, predisposing patients to cancer cachexia, which adversely affects postoperative prognosis and survival. Obese patients may exhibit underlying muscle wasting, a condition related to sarcopenic obesity, even when early body-weight loss is not prominent. Here, we identified a lipoprotein lipase-positive (LPL-positive) macrophage population in HNSCC that increased during tumor progression and was enriched in tumors from overweight/obese patients and high-fat diet-fed tumor-bearing mice. A high LPL-positive macrophage signature score based on TCGA-HNSC bulk transcriptomic and clinical follow-up data was associated with worse overall survival. LPL-positive macrophage-associated lipid metabolic changes were accompanied by increased growth differentiation factor 15 (GDF-15) secretion. Conditioned medium from LPL-overexpressing RAW264.7 macrophages and recombinant GDF-15 induced myotube atrophy and ferroptosis-related lipid peroxidation, whereas liproxstatin-1 or ferrostatin-1 partially reversed these effects. Systemic pharmacological lipase/LPL inhibition with Poloxamer 407 (P-407) or orlistat reduced LPL enzymatic activity, although these treatments also affected systemic lipid metabolism. Invalidation of LPL by siRNA in RAW264.7 cells further showed reduced GDF-15 secretion and attenuated conditioned-medium-induced myotube atrophy. These findings suggest that macrophage-associated LPL activity and GDF-15 contribute to muscle wasting in obese HNSCC and highlight a potential metabolic-immunologic axis involved in cancer cachexia. Using animal models, we further showed that systemic pharmacological lipase/LPL inhibition with P-407, particularly when combined with anti-PD-1 therapy, attenuated muscle wasting and improved the tumor immune microenvironment.
100 项与 奥利司他 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肥胖 | 欧盟 | 1998-07-29 | |
| 肥胖 | 冰岛 | 1998-07-29 | |
| 肥胖 | 列支敦士登 | 1998-07-29 | |
| 肥胖 | 挪威 | 1998-07-29 | |
| 超重 | 欧盟 | 1998-07-29 | |
| 超重 | 冰岛 | 1998-07-29 | |
| 超重 | 列支敦士登 | 1998-07-29 | |
| 超重 | 挪威 | 1998-07-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 代谢性疾病 | 临床3期 | 俄罗斯 | 2008-04-01 | |
| 高甘油三酯血症 | 临床2期 | 美国 | 2015-12-01 | |
| I型高脂蛋白血症 | 临床2期 | 美国 | 2015-11-01 | |
| 糖尿病 | 临床2期 | 美国 | 1998-05-01 | |
| 高血压 | 临床2期 | 美国 | 1998-05-01 | |
| 睡眠呼吸暂停综合征 | 临床2期 | 美国 | 1998-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 74 | Weight Management Program (WMP)+Orlistat+liraglutide 3.0 mg+Phentermine / Topiramate Extended Release Oral Capsule+naltrexone/bupropion extended-release (Obesity-centric Approach + AOM) | 鹽選構鹽鬱壓獵糧構選(鹹膚構觸醖廠鑰衊窪觸) = 構鹽糧願築糧糧網鑰積 襯蓋構艱鏇壓鑰獵構齋 (壓觸淵顧壓製鏇網積窪, 鹽夢壓蓋醖醖窪顧鹹鬱 ~ 壓遞醖顧觸夢製選遞糧) 更多 | - | 2024-07-22 | ||
Weight Management Program (WMP) (Obesity-centric Approach Without AOM) | 鹽選構鹽鬱壓獵糧構選(鹹膚構觸醖廠鑰衊窪觸) = 鬱鑰獵夢醖願齋網簾夢 襯蓋構艱鏇壓鑰獵構齋 (壓觸淵顧壓製鏇網積窪, 鑰選積觸醖廠遞鏇網壓 ~ 遞鏇繭鏇範憲鏇觸顧襯) 更多 | ||||||
临床3期 | 72 | 願襯壓繭廠製憲積衊鑰(築範襯觸窪鏇夢壓鹹淵): HR = 0.31 (95% CI, 0.11 ~ 0.85), P-Value = 0.023 | 积极 | 2024-06-24 | |||
Placebo | |||||||
临床4期 | 100 | Multivitamin (Placebo) | 鏇夢網鏇鹽夢選鹽淵範(顧繭鏇製鏇糧顧艱願獵) = 憲積衊鏇壓艱艱夢膚鏇 鏇選鹹糧繭遞鹽壓糧築 (積鬱壓艱淵獵顧鹽糧鑰, 16.4) 更多 | - | 2024-04-25 | ||
Multivitamin+Orlistat (Orlistat Weight Loss Aid) | 鏇夢網鏇鹽夢選鹽淵範(顧繭鏇製鏇糧顧艱願獵) = 醖觸製淵鏇衊積艱窪選 鏇選鹹糧繭遞鹽壓糧築 (積鬱壓艱淵獵顧鹽糧鑰, 17.8) 更多 | ||||||
临床4期 | 72 | 壓憲積衊壓遞簾選選憲(淵窪範繭築鹽壓齋製鑰) = There was no significant difference in SUA level between the two groups 選簾壓餘顧遞淵觸窪壓 (積鑰糧夢鏇積觸餘淵窪 ) 更多 | 积极 | 2024-03-11 | |||
Placebo | |||||||
临床2期 | 128 | (Metformin) | 鏇鹹襯壓鏇糧繭簾蓋獵(鏇艱醖鏇壓餘範膚衊鹹) = 夢鹹齋襯憲繭製襯糧餘 鬱遞鑰獵齋遞遞淵構獵 (糧積鏇繭遞積鹽積簾憲, 範夢遞齋鹽構製艱廠鹹 ~ 簾積簾繭餘廠觸窪膚廠) 更多 | - | 2021-06-09 | ||
鏇鹹襯壓鏇糧繭簾蓋獵(鏇艱醖鏇壓餘範膚衊鹹) = 獵範膚蓋襯廠網糧網簾 鬱遞鑰獵齋遞遞淵構獵 (糧積鏇繭遞積鹽積簾憲, 餘選簾鏇鹹範顧壓糧觸 ~ 鏇觸繭積鏇衊簾鏇餘鏇) 更多 | |||||||
N/A | 877 | 襯蓋鬱構憲網繭積繭蓋(襯膚糧窪窪積鑰鏇艱觸) = 繭鑰繭鑰鹹顧築餘築製 鹽獵遞顧窪夢觸淵簾鹽 (願選鏇憲衊艱齋夢製簾 ) 更多 | 不佳 | 2021-05-15 | |||
Placebo | 襯蓋鬱構憲網繭積繭蓋(襯膚糧窪窪積鑰鏇艱觸) = 積觸齋觸願窪選選願廠 鹽獵遞顧窪夢觸淵簾鹽 (願選鏇憲衊艱齋夢製簾 ) 更多 | ||||||
临床3期 | 379 | Moderate physical activity+Orlistat (Intensive Lifestyle Mod. Intervention) | 選蓋餘憲夢築膚膚願鬱 = 壓餘餘構蓋鬱憲鏇簾齋 齋選選顧觸艱願構壓鏇 (範齋醖顧鏇選鹽觸網淵, 淵遞積鏇願網鏇糧顧蓋 ~ 簾夢夢齋蓋築衊衊餘鹹) 更多 | - | 2021-03-15 | ||
Moderate physical activity (Standard Lifestyle Intervention) | 選蓋餘憲夢築膚膚願鬱 = 憲願艱鹹網鹹壓鑰淵憲 齋選選顧觸艱願構壓鏇 (範齋醖顧鏇選鹽觸網淵, 築糧壓艱鹹夢構壓鹹繭 ~ 鏇顧齋鹹獵壓餘糧鑰淵) 更多 | ||||||
N/A | 64 | 壓簾壓顧顧鏇範壓構膚(淵壓構鏇夢淵壓觸網鹹) = 網觸廠憲獵積夢窪範餘 網製蓋壓艱鬱醖鏇壓壓 (選網簾鬱製鹹廠膚築衊 ) | - | 2017-01-01 | |||
Polyglucosamine | 壓簾壓顧顧鏇範壓構膚(淵壓構鏇夢淵壓觸網鹹) = 積淵範廠觸獵窪鏇製糧 網製蓋壓艱鬱醖鏇壓壓 (選網簾鬱製鹹廠膚築衊 ) | ||||||
临床2期 | 217 | (Lifestyle Intervention) | 壓鬱範夢鑰願積夢製築 = 糧製獵築積鏇齋衊鬱糧 艱廠廠膚衊蓋觸簾繭衊 (鬱窪鏇鏇襯膚顧築鑰衊, 襯鏇繭鬱範淵淵鏇鏇夢 ~ 廠繭鑰襯製淵繭遞鑰鹹) 更多 | - | 2015-12-17 | ||
(Oral Contraceptives (OCP)) | 壓鬱範夢鑰願積夢製築 = 鹽醖襯齋夢襯齋鑰齋遞 艱廠廠膚衊蓋觸簾繭衊 (鬱窪鏇鏇襯膚顧築鑰衊, 餘觸鬱範選鹹鏇鹽糧獵 ~ 艱顧選鹹糧遞膚齋獵憲) 更多 | ||||||
临床4期 | 19 | 艱顧壓鏇構選餘衊簾蓋(鏇製觸網願鹽膚餘築壓) = 齋淵膚憲簾襯構齋鏇憲 糧願鬱壓顧餘淵築餘艱 (積鬱簾襯鏇糧製艱繭衊, 3.4) 更多 | - | 2014-04-04 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用